NasdaqCM - Nasdaq Real Time Price USD

Soleno Therapeutics, Inc. (SLNO)

Compare
48.95 +2.39 (+5.12%)
At close: August 30 at 4:00 PM EDT
48.95 0.00 (0.00%)
After hours: August 30 at 4:45 PM EDT
Loading Chart for SLNO
DELL
  • Previous Close 46.56
  • Open 46.40
  • Bid --
  • Ask --
  • Day's Range 45.90 - 49.13
  • 52 Week Range 3.69 - 53.82
  • Volume 475,543
  • Avg. Volume 529,272
  • Market Cap (intraday) 1.903B
  • Beta (5Y Monthly) -1.45
  • PE Ratio (TTM) --
  • EPS (TTM) -1.83
  • Earnings Date Nov 5, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 70.29

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

soleno.life

33

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SLNO

View More

Performance Overview: SLNO

Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SLNO
21.61%
S&P 500
18.42%

1-Year Return

SLNO
811.55%
S&P 500
25.59%

3-Year Return

SLNO
267.08%
S&P 500
25.26%

5-Year Return

SLNO
83.33%
S&P 500
93.14%

Compare To: SLNO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SLNO

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    1.90B

  • Enterprise Value

    1.64B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    6.78

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -25.55%

  • Return on Equity (ttm)

    -44.62%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -65.41M

  • Diluted EPS (ttm)

    -1.83

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    266.12M

  • Total Debt/Equity (mrq)

    0.10%

  • Levered Free Cash Flow (ttm)

    -23.13M

Research Analysis: SLNO

View More

Company Insights: SLNO

Research Reports: SLNO

View More

People Also Watch